## Phosphoramide mustard

MedChemExpress

®

Cat. No.:	HY-137316	
CAS No.:	10159-53-2	
Molecular Formula:	C <sub>4</sub> H <sub>11</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	$O_{N_{-}}$ , $NH_{2}$
Molecular Weight:	221.02	
Target:	DNA Alkylator/Crosslinker; Drug Metabolite	
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease	
Storage:	Please store the product under the recommended conditions in the Certificate of	
	Analysis.	

Description	Phosphoramide mustard is a biologically active metabolite of Cyclophosphamide (HY-17420), with anticancer activitiy. Phosphoramide mustard induces DNA damage <sup>[1][2]</sup> .			
IC <sub>50</sub> & Target	DNA Alkylator <sup>[1]</sup>			
In Vitro	PNAAlkylator <sup>[1]</sup> Phosphoramide mustard causes cytotoxicity through forming cross-linked DNA adducts which inhibit DNA strand during replication <sup>[1]</sup> .   Phosphoramide mustard (3-6 µM; 48 hours) reduces cell viability in rat spontaneously immortalized granulosa ce [1].   Phosphoramide mustard (3-6 µM; 24-48 hours) induces DNA adduct formation and ovarian DNA damage <sup>[1]</sup> .   Phosphoramide mustard (3-6 µM; 24-48 hours) induces DNA adduct formation and ovarian DNA damage <sup>[1]</sup> .   Phosphoramide mustard (3-6 µM; 24-48 hours) increases DNA damage responses (DDR) gene mRNA expression le DDR proteins <sup>[1]</sup> .   MCE has not independently confirmed the accuracy of these methods. They are for reference only.   Cell Line: SIGCs   Concentration: 0.5 µM, 1 µM, 3 µM, 6 µM   Incubation Time: 48 hours   Result: Reduced cell viability at concentrations of 3 µM and higher.   RT-PCR <sup>[1]</sup> SIGCs   Concentration: 3 µM, 6 µM   Incubation Time: 24 hours, 48 hours   Result: Increased DDR gene mRNA expression levels.			
	western Blot Analysis <sup>[1]</sup>			

Inhibitors • Screening Libraries •

Proteins

	Cell Line:	SIGCs	
	Concentration:	3 μΜ, 6 μΜ	
	Incubation Time:	24 hours, 48 hours	
	Result:	Generally increased DDR proteins.	
In Vivo	Phosphoramide mustard (2.1-20.7 mg/kg; i.p.; daily; for 5 days) inhibits subcutaneous tumor growth in rats <sup>[2]</sup> . Phosphoramide mustard exhibits terminal elimination half-lives (rat 15.1 min) following intravenous administration (rat 59.4 mg/kg) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Rat, subcutaneously implanted Walker 256 carcinosarcoma tumor <sup>[2]</sup>	
	Dosage:	2.1 mg/kg, 4.8 mg/kg, 10.4 mg/kg, 20.7 mg/kg	
	Administration:	Intraperitoneal injection, once daily, for 5 consecutive days	
	Result:	Required to produce 50% inhibition of subcutaneous tumor growth with dose of 12 mg/kg.	
	Animal Model:	Rats <sup>[2]</sup>	
	Dosage:	59.4 mg/kg (Pharmacokinetic Analysis)	
	Administration:	Intravenous injection	
	Result:	T <sub>1/2</sub> (15.1 min).	

## REFERENCES

[1]. Shanthi Ganesan, et al. Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells. Toxicol Appl Pharmacol. 2015 Feb 1; 282(3): 252–258.

[2]. S Genka, et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol. 1990;27(1):1-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

09 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA